Novartis CEO: No on megadeals, yes on medium-sized buyouts

Novartis ($NVS) CEO Joe Jimenez isn't reluctant to rule out megadeals in positioning the giant pharma for the future. But the right kind of "medium-sized" deals, all the rage these days in the biopharma industry, would be fine. The acquisition strategy, though, will have to be tailored to continue the company's dividend support plan. Story

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.